Thank good everyone. afternoon, and Ron, you,
up to million our and As million XX% the compared consistent quarter in in pre-announcement, quarter with $XX.X fourth RxSight compared quarter third the reported million, XXXX. $X.X of to ago $XX.X January up XX% of revenue year
broad-based, was as clinical volumes. of and Delivery support well installed rising positive we economic manner. a surgeon trends sharp Light LAL benefits and Devices of practices expansion system in base to continued a efficient and offer as the our increase in ensure provide reflecting These are RxSight tangible the the recognition LAL Growth delivers that our can solution both new procedure smooth high-touch reflect of
the We the up period quarter's the third quarter sold LDDs and equipment expectations ago in units of strong in capital XXXX, the unit the purchases. when XXXX, XX% third growth quarter XX in overcame XX LDD fourth to seasonality for of XX% XX compared to slower up the usual year compared units
the in quarter versus superior quarter Fourth the XX% of revenue, XXXX XX% up We versus preference quarter LAL performance to of quarter in units, continue installed sales the our million the XXXX base third clinical XXXX. XX% an $X.X LDD of end with the XX% XXX and up and year-end of ended growing LDD for rise reflecting ago year versus of versus XXXX, generated up XXXX customizable patients quarter unit and of IOL. third surgeons fourth XXXX. up placements the
million XX% ago of LAL to third $X.X up revenue quarter quarter in These of the XXX% XXXX units the the into the from quarter year We in XXXX. units the from $X compared of up in XXXX, and the million $X.X the fourth XXX% translated fourth quarter up and volumes XXXX. X,XXX LALs to sold third million quarter X,XXX compared of period, up in X,XXX procedure the in in the of XX%
the shift Higher in revenue XXXX XX% of the XX% also mix quarter fourth of to in compared LAL quarter of LAL XX% and drove in total volumes a third revenue representing XXXX. of same fourth in This XXXX quarter XX.X% XXXX, quarter to XX% compared dynamic gross margin quarter XX.X% in of XXXX. the in helped to our to fourth and of the the expand third with
million quarter the quarter a expenses major versus a personnel, XXXX, latter increase. sequential and were up due new Fourth XXXX the of in X% primarily incentive meeting, in rose compensation On early $XX.X $XX.X $XX.X part SG&A on XX% hired professional year increased third with XXXX basis, sales, and higher costs drove marketing revenue. in expenses XXXX million, higher and ago increased from quarter, to the of SG&A commercial million associated we travel
expenses of Research third clinical compared quarter in for typical studies. were to the business quarter-to-quarter are year of R&D which clinical $X.X XXXX. costs, timing and our compared quarter changes up These utilization $X.X the fourth to reflect and fluctuations include million XX% of regulatory, and and in material the in in XXXX up and million, primarily development $X.X million X% for ago quarter
We reported and million diluted per of on outstanding and of shares share a basis. of In the our shares. in year quarter net the million or $X.XX a per fourth basic of a weighted million, $XX.X using $XX.X loss loss $X.XX loss basic XX was or ago diluted net shares quarter, XXXX average
a comparative is and quarter non-GAAP stock-based million disclosure with of to million, in today's resulting release XXXX non-GAAP useful also provide $X.XX share. of loss for Note investors. included diluted a fourth in compensation was per press A in that loss information or $XX.X the $X basic
of compared a and LDD by Revenue In interest to driven XXX% recap XXX% a provide the million, $XX and increase XXXX results respectively. revenue, in XXXX. XX% very brief LAL year rose I'll time, of to full
rose investments margin the XX% XX.X% increased our XX% travel. versus meetings gross of million in-person primarily ophthalmic expenses expand to scope resumption in and Our SG&A XXXX. was and size XXXX commercial to to organization, $XX.X of due made
on XXXX, our growth a million $XX.X loss SG&A We $XX.X in $XX in expenses rose R&D of spending X% versus execute million. net to million loss a to increased primarily strategy. net of reported XXXX reflecting
stock-based million Excluding $XX.X non-GAAP basic or loss the diluted was XXXX, million our $XX.X in share. $X per and compensation
cash, year quarter. investments, including ended stock $XXX.X market the cash in to million proceeds at short-term in balance sheet. net from offering through with common the in our and We fourth and Moving of $X million the equivalents sale the the
year-end discounts commissions of and $XX.XX At of of stock long-term public expenses. and million. common first ATM debt was $XX.X our $XX.X sales to-date, XXXX, through In XXXX common million offering net approximately the expenses stock raised additional a and per before underwriting shares our we and offering X.X share of of at quarter million fees
first and in net ATM before proceeds adjusted $XX.X at million our was of from cash Rolling million in and $XXX.X the approximate public offering, and cash, our investments of cash XXXX. XX our equivalents short-term balance quarter the use December cash
you XXXX. first updates, those estimate average our quarter weighted XX.X of making For in we the be of shares outstanding modeling to million approximately
in guidance to be range million $XX XXXX revenue is $XX for XX%. Our to year-over-year XX% implying the million of of to growth
growth We some to related the sales. in quarters see expect expected third primarily first with seasonality to sequential and quarterly equipment capital
to margin constraints a increased part from in offset which due We XX%, LDD expect inflationary partially a our chain procedure much expand higher LAL lingering to carry gross reflecting margin an range sales, by of volumes the supply revenue gross contribution and to lower pressures. XX% margin to
and We manufacture depending components XXXX the second to our half on LDD sometime continue of in to anticipate cost availability the launch lower of parts. reliable of
light operating post-operative $XXX $XXX large represents to a expect over of We the investments support treatment which LAL establish XXXX, procedure million, be an to to expense XX% durable and reflects to sustained between and making ongoing XX% growth. increase and million we’re infrastructure
operating expense in $XX of non-cash our $XX Included is compensation expense primarily in million. million cost to stock-based
We cash interest equivalents the to income largely will ATM and million higher offering cash, expense offset expect on by marketable debt securities that interest our and proceeds. $XX our due by with
quarter basis expenses. on projections, the pay use accrued Based year other cash of compensation on for for accrued quarterly higher we a expect decreasing XXXX use anticipate we incentive as cash these except all and expenses when first we
debt do operations. incur to order anticipate need to addition, capital reach raise the not or additional from In we profit additional in
back call to Ron. With turn that, I’ll the